The Division of Oncological Sciences aims to better understand cancer through basic, translational and population-based research that improves cancer prevention, detection and treatments for all.
Our community of faculty, trainees and staff brings together scientists from a broad range of disciplines and works collaboratively to advance innovation and translate discoveries from the lab into meaningful impacts for cancer patients and our community.
Based in team science, our research centers on four areas:
The aim of Precision Systems Oncology is to decipher mechanisms of dynamically interacting biological ecosystems and emergent properties, to understanding cell state transitions, immune evasion, therapy-resistance, and early tumor dissemination. A foremost priority is to better understand cell plasticity by gaining the ability to experimentally decipher transitions from normal to cancer, cancer to metastasis and metastasis to resistance.
This section is a biology-based interdisciplinary field focused on complex interactions within biological systems, using a holistic approach to biological research. This section encompasses researchers interested in analytics of the tumor and tumor ecosystem including individuals who are generating diverse quantitative datasets as well as individuals with computational and mathematical expertise to integrate these data to model complex biological systems and, thereby, obtain a deeper understanding of the molecular origins, evolution, treatment vulnerabilities, and treatment adaptations of cancer.
This section includes Precision Early Detection through the Cancer Early Detection Advanced Research (CEDAR) center and Precision Oncology through the SMMART program. Both programs rely on the integration of emerging capabilities in imaging and OMICS technologies, innovative model systems, cohort building and unique clinical trials to generate novel insights, development and translation of discoveries to practice.
Cancer data science describes the interdisciplinary quantitative approaches that draw from machine learning, statistics and computer science to solve biological problems relevant to cancer. The field often grapples with large and unstructured data and strives toward integrating information from many sources. The goal is to develop an understanding of the causes of real world problems such as predicting cancer vulnerabilities, understanding the etiologic causes of cancer, and predicting cellular behaviors. The newly formed Center for Biomedical Data Sciences (jointly with University of Oregon) serves as a nexxus for advancing research in this area. This section includes researchers interested in solving cancer problems using computational, informatic and statistical tools and approaches.
The primary objective of the Chemical Biology and Experimental Therapeutics (CBET) is to translate the basic research into drug discovery and development projects. CBET brings together innovative tools and approaches derived from chemistry to provide an unprecedented view of previously unseen processes in living systems. This section includes translational research through the Center for Experimental Therapeutics (CET), which spans the entire spectrum of novel therapeutic screening, preclinical model development and testing, and translation to clinical trials. This section has a diverse group of researchers interested in employing the tools of synthetic chemistry, molecular modeling, imaging and chemical biology to understand disease biology, and for translational research in drug discovery, development, imaging and radiation.
Cancer population science studies cancer etiology and identifies environmental, behavioral, social and genetic factors associated with cancer risk and outcomes in individuals and communities. The field tests new interventions that impact the population burden of cancer: incidence, progression, survival and overall burden of disease. Beyond this, the field utilizes population-based designs informed by theories of community engagement to deploy novel molecular and phenotypic predictors, biomarkers, diagnostics and therapies, and behavioral interventions to most effectively reduce overall burden and to narrow racial/ethnic and other disparities in disease outcomes.
This section includes researchers interested in studying genetics, behaviors and exposures at a population level that increase the risk of developing cancer. CPS researchers also investigate different approaches for prevention, early detection, treatment and survivorship that are investigated in and/or rapidly translated to individuals, communities, and populations. In alignment with the precision health focus of the Knight Cancer Institute, CPS science is ultimately grounded in a precision-public health framework where the right intervention can be delivered to the right population at the right time, every time.
Robust technology and resources for cancer researchers
The Division of Oncological Sciences has access to state-of-the-art technology, resources and expertise to help our investigators reach their scientific goals, including:
- Advanced Multiscale Microscopy
- BioLibrary and Pathology
- Flow Cytometry
- Integrated Genomics
Check out the Cancer Translated blog
Brought to you by the OHSU Knight Cancer Institute, the Cancer Translated blog explores new findings, ideas and debates in cancer research and treatment – from basic biology and clinical trials to prevention and survivorship.
OHSU expands capacity for cancer clinical trials
OHSU installs state-of-the-art PET/MRI scanner for clinical care and research
OHSU study advances field of precision medicine
AstraZeneca selects OHSU Knight Cancer Institute as global ‘partner of choice’
‘Bone in a dish’ opens new window on cancer initiation, metastasis, bone healing
Investigational blood test could detect many types of cancer with one blood draw
OHSU, UO join forces to combat cancer with data science